Improving Assay performance when complex sample pre-treatment is required – a CRO perspective

Laura Geary Senior Scientist

Proven expertise. Worldwide access.

Case Studies



Improving assay performance in a heat treatment assay



Improving analyst to analyst variation in a PandA assay



Improving precision in BEAD assays

Introduction


Complex sample pre-treatment methods are sometimes required to achieve the high levels of drug tolerance requested by sponsors

ACE, precipitation, SPEAD, bead methods and heat treatment


These techniques can be:

- Time consuming
- Have poor precision
- Require specialized equipment

ARE WE DOING TOO MUCH?









Introduction

ARE WE DOING TOO MUCH?

- A CRO needs to meet the requirements of the sponsor
- We need to know the level of drug expected in the ADA samples
- Complex sample pre-treatment is still required in some cases





Case Study 1: Heat treatment



When it is required:


- Reduce matrix effects
- Improve drug tolerance to non-IgG therapeutics

Potential Assay problems:

- Changes to the matrix consistency leading to poor precision
- Evaporation of samples during heating leading to poor precision
- Denaturation of the PC
- Changes to pH due to the temperature change

Case Study 1: Heat treatment





Contro	_	√%
Control	Intra Assay	Inter Assay
HPC	<10	<10
MPC	<10	<10
LPC	<10	<30
NC	<10	<50



Case Study 1: Heat treatment


CRO Solutions:

Use specific tubes with screw cap lids


• Use hea		CV%		nensions	
• Set mir	Control	Intra Assay	Inter Assay	mple volumes	
	HPC	<5	<5		
	MPC	<5	<5		
	LPC	<5	<10		
	NC	<5	<15		



Case Study 2: Improving analyst to analyst variation in a PandA assay



Case Study 2: Improving analyst to analyst variation in a PandA assay





Case Study 2: Improving analyst to analyst variation in a PandA assay

Manual pellet wash


Automated pellet wash

	Screen (S/N)			Screen RLU
	HPC	MPC	LPC	NC
Inter Mean	224.5	24.26	3.45	86
Inter %CV	28.8	30.4	20.3	5.2
Max Intra-assay % CV	10	9.7	7.2	4.2


	Screen (S/N)			Screen RLU
	HPC	MPC	LPC	NC
Inter Mean	355.07	41.63	5.24	61
Inter %CV	7.1	6.9	6.7	8.3
Max Intra-assay % CV	9.5	8	7.9	10.1




BIOANALYTICS



Validation Intra-Assay Precision - manual bead steps





The solution



KingFisher Flex










KingFisher Flex










 Poor precision seen, particularly in the NC with manual bead processing method

	1-2	5-6
Α	NC	NC
В	HPC	Blank individual

	1-2	5-6
Α	15000	46
В	120000	55





Inter-assay precision using automated bead processing

	CV%		
Control	Screen S/N	Confirmator y	
HPC	<10	<1	
MPC	<15	<]	
LPC	<19	<10	
NC	<15 (RLU)	<10	




Intra-assay precision using automated bead processing

	CV %		
Control	Screen S/N	Confirmatory	
HPC	<3	<]	
MPC	<5	<]	
LPC	<5	<3	
NC	<5 (RLU)	<10	

KingFisher Protocol optimisation:

- Incubation times
- Shaking times and speeds
- Buffers
 - Inclusion of detergent





Summary

Complex sample pre-treatment is often required for immunogenicity assays

- They can have poor precision and poor assay performance
- The simple assay formats should be assessed first
 - Accurate drug tolerance levels are required

There are methods to eliminate the assay variability

- Ensuring consumables remain consistent e.g. screw cap tubes to heat samples
- Use automation and electronic equipment where possible

Our recommendations

- Heat treatment can only be used to improve drug tolerance with a non-IgG therapeutic
- You can achieve high levels of drug tolerance with PandA, but you may encounter the licensing problems
- Automated bead-based methods are simple and achieve high levels of drug tolerance

Acknowledgements

Resolian IA Department colleagues

References Images Created on BioRender.com

Thank you for listening,

Any questions?